Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect.

Wit JM, Rekers-Mombarg LT, Cutler GB, Crowe B, Beck TJ, Roberts K, Gill A, Chaussain JL, Frisch H, Yturriaga R, Attanasio AF

The Journal of pediatrics1 Jan 2005Cited by 89 (Europe PMC)

PMID15644821DOI10.1016/j.jpeds.2004.08.055PepBankPUB-15644821

Publisher page PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In children with idiopathic short stature, GH at 0.37 versus 0.24 mg/kg/week increased adjusted final height by 0.57 SDS (3.6 cm; P = .025).
In plain wordsIn children with idiopathic short stature, GH at 0.37 mg/kg/week increased final height more than 0.24 mg/kg/week.
Peptide
HGH (somatotropin)
Outcome
IncreaseAdjusted final height dose contrast
Study
n: not reported in source
Comparator
0.24 mg/kg/week GH
Analysis
Primary
Outcome group
Linear growth · Endocrine and hormones
Studied dose
0.37 mg/kg/week · Mean 6.5 yearsAs given in this study (human).
Measurements
Adjusted mean treatment difference in final height, 0.37 vs 0.24 mg/kg/week
0.57 SDS
adjusted for baseline predicted height SDS
Adjusted mean treatment difference in final height, 0.37 vs 0.24 mg/kg/week
3.6 cm
adjusted for baseline predicted height SDS
P value
0.025 P
0.37 vs 0.24 mg/kg/week
Source sentences
Summary
For the primary comparison between the 0.37 mg/kg/week and 0.24 mg/kg/week dose groups, the mean treatment difference (adjusted for differences in baseline predicted height SDS) was 0.57 SDS (3.6 cm; P = .025).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate in an open-label randomized study, the effect of two doses of growth hormone (GH) on final height and height velocity during the first 2 years of treatment of children with idiopathic short stature (mean baseline height standard deviation score [SDS] -3.2).
Summary · context
Patients were treated with GH at 0.24 mg/kg/week, 0.24 mg/kg/week for the first year and at 0.37 mg/kg/week thereafter (0.24-->0.37), or 0.37 mg/kg/week.
Report a problemFND-1564482106
02HumanRandomized controlled trialEfficacy outcome
In children with idiopathic short stature, GH at 0.37 mg/kg/week increased height velocity by 0.8 cm/year more than 0.24 mg/kg/week (P = .003).
In plain wordsIn children with idiopathic short stature, GH at 0.37 mg/kg/week increased growth speed more than 0.24 mg/kg/week.
Peptide
HGH (somatotropin)
Outcome
IncreaseHeight velocity versus low dose
Study
n = 142
Comparator
0.24 mg/kg/week GH
Outcome group
Linear growth · Endocrine and hormones
Studied dose
0.37 mg/kg/week · First 2 yearsAs given in this study (human).
Measurements
Height velocity treatment difference, 0.37 vs 0.24 mg/kg/week
0.8 cm/year
first 2 years, n = 72 vs n = 70
P value
0.003 P
0.37 vs 0.24 mg/kg/week
Source sentences
Summary
Patients who received 0.37 mg/kg/week (n = 72) experienced a significantly greater increase in height velocity than those who received 0.24 mg/kg/week (n = 70) (treatment difference = 0.8 cm/year; P = .003) or 0.24-->0.37 mg/kg/week (n = 67) (treatment difference = 0.9 cm/year; P = .001).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate in an open-label randomized study, the effect of two doses of growth hormone (GH) on final height and height velocity during the first 2 years of treatment of children with idiopathic short stature (mean baseline height standard deviation score [SDS] -3.2).
Summary · context
Patients were treated with GH at 0.24 mg/kg/week, 0.24 mg/kg/week for the first year and at 0.37 mg/kg/week thereafter (0.24-->0.37), or 0.37 mg/kg/week.
Report a problemFND-1564482101
03HumanRandomized controlled trialEfficacy outcome
In children with idiopathic short stature, GH at 0.37 mg/kg/week increased height velocity by 0.9 cm/year more than escalating-dose GH (P = .001).
In plain wordsIn children with idiopathic short stature, GH at 0.37 mg/kg/week increased growth speed more than escalating-dose GH.
Peptide
HGH (somatotropin)
Outcome
IncreaseHeight velocity versus escalating dose
Study
n = 139
Comparator
0.24-->0.37 mg/kg/week GH
Outcome group
Linear growth · Endocrine and hormones
Studied dose
0.37 mg/kg/week · First 2 yearsAs given in this study (human).
Measurements
Height velocity treatment difference, 0.37 vs 0.24-->0.37 mg/kg/week
0.9 cm/year
first 2 years, n = 72 vs n = 67
P value
0.001 P
0.37 vs 0.24-->0.37 mg/kg/week
Source sentences
Summary
Patients who received 0.37 mg/kg/week (n = 72) experienced a significantly greater increase in height velocity than those who received 0.24 mg/kg/week (n = 70) (treatment difference = 0.8 cm/year; P = .003) or 0.24-->0.37 mg/kg/week (n = 67) (treatment difference = 0.9 cm/year; P = .001).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate in an open-label randomized study, the effect of two doses of growth hormone (GH) on final height and height velocity during the first 2 years of treatment of children with idiopathic short stature (mean baseline height standard deviation score [SDS] -3.2).
Summary · context
Patients were treated with GH at 0.24 mg/kg/week, 0.24 mg/kg/week for the first year and at 0.37 mg/kg/week thereafter (0.24-->0.37), or 0.37 mg/kg/week.
Report a problemFND-1564482102
04HumanRandomized controlled trialSafety outcome
In children with idiopathic short stature, GH dose had no effect on safety parameters.
In plain wordsIn children with idiopathic short stature, safety measures did not differ by GH dose.
Peptide
HGH (somatotropin)
Outcome
No significant changeSafety parameters by dose
Study
n: not reported in source
Comparator
Other GH dose group
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Mean overall height gains (final height minus baseline predicted height) were 7.2 cm and 5.4 cm for the 0.37 mg/kg/week and 0.24 mg/kg/week dose groups, respectively, without dose effects on safety parameters.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate in an open-label randomized study, the effect of two doses of growth hormone (GH) on final height and height velocity during the first 2 years of treatment of children with idiopathic short stature (mean baseline height standard deviation score [SDS] -3.2).
Summary · context
Patients were treated with GH at 0.24 mg/kg/week, 0.24 mg/kg/week for the first year and at 0.37 mg/kg/week thereafter (0.24-->0.37), or 0.37 mg/kg/week.
Report a problemFND-1564482109
05HumanNon-randomized trialEfficacy outcome
In children with idiopathic short stature, height SDS increased by 1.55 with GH at 0.24 mg/kg/week.
In plain wordsIn children with idiopathic short stature, height scores increased from baseline with GH at 0.24 mg/kg/week.
Peptide
HGH (somatotropin)
Outcome
IncreaseHeight SDS increase with low dose
Study
n: not reported in source
Outcome group
Linear growth · Endocrine and hormones
Studied dose
0.24 mg/kg/week · Mean 6.5 yearsAs given in this study (human).
Measurements
Mean height SDS increase at final height
1.55 SDS
0.24 mg/kg/week group, 50 patients with final height across the three groups
Source sentences
Summary
For the 50 patients for whom final height measurements were available, mean height SDS increased by 1.55, 1.52, and 1.85 SDS, respectively, for the three dose groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were treated with GH at 0.24 mg/kg/week, 0.24 mg/kg/week for the first year and at 0.37 mg/kg/week thereafter (0.24-->0.37), or 0.37 mg/kg/week.
Summary · context
To investigate in an open-label randomized study, the effect of two doses of growth hormone (GH) on final height and height velocity during the first 2 years of treatment of children with idiopathic short stature (mean baseline height standard deviation score [SDS] -3.2).
Report a problemFND-1564482103
06HumanNon-randomized trialEfficacy outcome
In children with idiopathic short stature, height SDS increased by 1.52 with escalating-dose GH.
In plain wordsIn children with idiopathic short stature, height scores increased from baseline with escalating-dose GH.
Peptide
HGH (somatotropin)
Outcome
IncreaseHeight SDS increase with escalating dose
Study
n: not reported in source
Outcome group
Linear growth · Endocrine and hormones
Studied dose
0.24 mg/kg/week for first year, then 0.37 mg/kg/week · Mean 6.5 yearsAs given in this study (human).
Measurements
Mean height SDS increase at final height
1.52 SDS
0.24-->0.37 mg/kg/week group, 50 patients with final height across the three groups
Source sentences
Summary
For the 50 patients for whom final height measurements were available, mean height SDS increased by 1.55, 1.52, and 1.85 SDS, respectively, for the three dose groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were treated with GH at 0.24 mg/kg/week, 0.24 mg/kg/week for the first year and at 0.37 mg/kg/week thereafter (0.24-->0.37), or 0.37 mg/kg/week.
Summary · context
To investigate in an open-label randomized study, the effect of two doses of growth hormone (GH) on final height and height velocity during the first 2 years of treatment of children with idiopathic short stature (mean baseline height standard deviation score [SDS] -3.2).
Report a problemFND-1564482104
07HumanNon-randomized trialEfficacy outcome
In children with idiopathic short stature, height SDS increased by 1.85 with GH at 0.37 mg/kg/week.
In plain wordsIn children with idiopathic short stature, height scores increased from baseline with GH at 0.37 mg/kg/week.
Peptide
HGH (somatotropin)
Outcome
IncreaseHeight SDS increase with high dose
Study
n: not reported in source
Outcome group
Linear growth · Endocrine and hormones
Studied dose
0.37 mg/kg/week · Mean 6.5 yearsAs given in this study (human).
Measurements
Mean height SDS increase at final height
1.85 SDS
0.37 mg/kg/week group, 50 patients with final height across the three groups
Source sentences
Summary
For the 50 patients for whom final height measurements were available, mean height SDS increased by 1.55, 1.52, and 1.85 SDS, respectively, for the three dose groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were treated with GH at 0.24 mg/kg/week, 0.24 mg/kg/week for the first year and at 0.37 mg/kg/week thereafter (0.24-->0.37), or 0.37 mg/kg/week.
Summary · context
To investigate in an open-label randomized study, the effect of two doses of growth hormone (GH) on final height and height velocity during the first 2 years of treatment of children with idiopathic short stature (mean baseline height standard deviation score [SDS] -3.2).
Report a problemFND-1564482105
08HumanNon-randomized trialEfficacy outcome
In children with idiopathic short stature, final height exceeded baseline predicted height by 7.2 cm with GH at 0.37 mg/kg/week.
In plain wordsIn children with idiopathic short stature, final height exceeded predicted height by 7.2 cm with GH at 0.37 mg/kg/week.
Peptide
HGH (somatotropin)
Outcome
IncreaseOverall height gain with high dose
Study
n: not reported in source
Comparator
Baseline predicted height
Outcome group
Linear growth · Endocrine and hormones
Studied dose
0.37 mg/kg/week · Mean 6.5 yearsAs given in this study (human).
Measurements
Mean overall height gain (final height minus baseline predicted height)
7.2 cm
0.37 mg/kg/week group
Source sentences
Summary
Mean overall height gains (final height minus baseline predicted height) were 7.2 cm and 5.4 cm for the 0.37 mg/kg/week and 0.24 mg/kg/week dose groups, respectively, without dose effects on safety parameters.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate in an open-label randomized study, the effect of two doses of growth hormone (GH) on final height and height velocity during the first 2 years of treatment of children with idiopathic short stature (mean baseline height standard deviation score [SDS] -3.2).
Summary · context
Patients were treated with GH at 0.24 mg/kg/week, 0.24 mg/kg/week for the first year and at 0.37 mg/kg/week thereafter (0.24-->0.37), or 0.37 mg/kg/week.
Report a problemFND-1564482107
09HumanNon-randomized trialEfficacy outcome
In children with idiopathic short stature, final height exceeded baseline predicted height by 5.4 cm with GH at 0.24 mg/kg/week.
In plain wordsIn children with idiopathic short stature, final height exceeded predicted height by 5.4 cm with GH at 0.24 mg/kg/week.
Peptide
HGH (somatotropin)
Outcome
IncreaseOverall height gain with low dose
Study
n: not reported in source
Comparator
Baseline predicted height
Outcome group
Linear growth · Endocrine and hormones
Studied dose
0.24 mg/kg/week · Mean 6.5 yearsAs given in this study (human).
Measurements
Mean overall height gain (final height minus baseline predicted height)
5.4 cm
0.24 mg/kg/week group
Source sentences
Summary
Mean overall height gains (final height minus baseline predicted height) were 7.2 cm and 5.4 cm for the 0.37 mg/kg/week and 0.24 mg/kg/week dose groups, respectively, without dose effects on safety parameters.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate in an open-label randomized study, the effect of two doses of growth hormone (GH) on final height and height velocity during the first 2 years of treatment of children with idiopathic short stature (mean baseline height standard deviation score [SDS] -3.2).
Summary · context
Patients were treated with GH at 0.24 mg/kg/week, 0.24 mg/kg/week for the first year and at 0.37 mg/kg/week thereafter (0.24-->0.37), or 0.37 mg/kg/week.
Report a problemFND-1564482108
10HumanNon-randomized trialEfficacy outcome
Among children with idiopathic short stature continuing GH at 0.37 mg/kg/week to final height, 94% reached the normal adult height range.
In plain wordsAmong children with idiopathic short stature continuing GH at 0.37 mg/kg/week to final height, 94% reached normal adult height.
Peptide
HGH (somatotropin)
Outcome
Not applicableNormal adult final height
Study
n: not reported in source
Outcome group
Linear growth · Endocrine and hormones
Studied dose
0.37 mg/kg/week · Mean 6.5 yearsAs given in this study (human).
Measurements
Patients with final height in the normal adult range
94%
randomized to 0.37 mg/kg/week and continued to final height
Source sentences
Summary
Final height measurements were within the normal adult height range for 94% of patients randomized to 0.37 mg/kg/week who continued to final height.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate in an open-label randomized study, the effect of two doses of growth hormone (GH) on final height and height velocity during the first 2 years of treatment of children with idiopathic short stature (mean baseline height standard deviation score [SDS] -3.2).
Summary · context
Patients were treated with GH at 0.24 mg/kg/week, 0.24 mg/kg/week for the first year and at 0.37 mg/kg/week thereafter (0.24-->0.37), or 0.37 mg/kg/week.
Report a problemFND-1564482110

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.